Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world.
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world.
The 510k medical device regulatory pathway is typically the most economical and fastest path to approval. In addition to the typical application information, the 510k requires a summary of the scientific data to support the device, as well as a comparison to a predicate device. Medical devices that are successful in foreign markets on the merit of their scientific evidence are obvious candidates for introduction into a US market. The 510k pathway allows foreign manufacturers to submit a summary of this data to the FDA, who can then approve their device for sale in the US market.
The 510k’s Section 12: Substantial Equivalence Discussion, where the predicate device(s) is/are selected, tends to be the most technically and scientifically challenging aspects of a submission for ex-US approved medical devices. While ex-US manufacturers are familiar with their own markets and competitors, they must select a US-approved device(s) that is most similar to their device in a number of different aspects. The purpose of the “predicate device” section of a 510k application is to convince the FDA that there is precedent for the safety and efficacy of the new device, such that a more extensive premarket notification or de novo application would not be required.
The FDA has outlined their thought processes for the most compelling 510k predicate device selection and justification. After helping many foreign companies with 510k submissions, ISS recommends reading this guidance thoroughly to gain a baseline understanding of the necessary considerations for developing a predicate device section.
In addition to these fundamental requirements, which should only be considered as the minimum that should be considered when pursuing a 510k pathway, there are several other strategies ISS has found that has helped improve the success of a 510k submission:
Inclusion of foreign predicate devices
Inclusion of multiple US predicate devices for devices with unique characteristics
ISS has identified the tips described in this post as crucial to success when developing the predicate device section in a 510k submission. Researching compelling predicate device data and creating a strong scientific narrative is crucial for 510k success. A rejected 510k submission means a sponsor must resort to the significantly more costly premarket notification or de novo pathways. ISS has assisted dozens of clients and our expertise and experience can help you achieve success. Contact us today if you are considering a 510k submission.
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
According to FDA regulation, conventional food and dietary supplements are allowed to make three categories of claims: health claims, nutrient content claims, and structure/function claims. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today
Contact us